Acute Agitation and Aggression Treatment Market Trends, 2021-2031

Acute Agitation and Aggression Treatment Market (Treatment Approach: Behavioral Approaches, Environmental Interventions, and Pharmacologic Approaches [Drugs]; Indication: Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-induced Agitation & Aggression, Alcohol Withdrawal, and Others; Route of Administration: Oral, Intramuscular, and Others; and End-user: Hospitals & Ambulatory Surgical Centers, Psychiatric Care Facilities, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Pharmacies Increase Digital Visibility to Offer Affordable Medications amid Coronavirus Pandemic

Telehealth services and mental health apps are storming the acute agitation and aggression treatment market during the ongoing coronavirus pandemic. Since increasing number of individuals are unable to afford treatment or medications, affordable telehealth services and mental health apps are helping to reduce anxiety among individuals.

Online pharmacies in the acute agitation and aggression treatment market are increasing their visibility digitally to help individuals compare the prices of medications. Manufacturers are maintaining optimum inventory levels to ensure a continuous supply of therapeutics. An increasing number of pharmaceutical companies are providing coupons and price reduction promo codes to help individuals purchase medications. Even insurance providers are refilling the prescription of patients well before the refill date in order to improve patient quality of life.

acute agitation and aggression treatment market infographic

To know the scope of our report Get a Sample on Acute Agitation and Aggression Treatment Market

Research Investment Helps in Development of Well-tolerated Antidepressants

Like all medications, even antidepressants are associated with side effects such as headache, nausea, and insomnia in many cases. Hence, companies in the acute agitation and aggression treatment market are continuously investing in R&D to develop improved formulations of antidepressants. As such, antidepressants such as serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and atypical antidepressants are well-tolerated in individuals.

In order to reduce reliance on antidepressants, healthcare providers are increasing emphasis on behavioral approaches including lifestyle changes, brain stimulation therapies, and integrative medicines in order to improve patient outcomes. There is a growing awareness about different forms of psychotherapy that are helping patients suffering from depression. Cognitive behavioral therapy (CBT), diet changes, and family therapy are being publicized to improve patient quality of life.

Get a glimpse of the in-depth analysis through our Report Brochure

Benzodiazepines Gain Prominence in Emergency Department for Rapid Treatment of Acute Agitation

The acute agitation and aggression treatment market is predicted to expand at a modest CAGR of 5.1% during the forecast period. Manufacturers are increasing the production of benzodiazepines for the rapid treatment of acute agitation in the emergency department (ED). Benzodiazepines are being known for sedating an undifferentiated patient without obvious delirium or psychiatric disease. However, benzodiazepines carry the risk of creating a paradoxical reaction in patients, especially the elderly and young population. As such, it has been found that benzodiazepines are well-tolerated and adverse reactions are rare.

Healthcare providers in the acute agitation and aggression treatment market are increasing awareness that benzodiazepines carry the risk for respiratory depression and hence must be avoided for patients who have ingested other depressant medications.

Lorazepam Being Publicized for Effective Treatment of Acutely Agitated Patients

The acute agitation and aggression treatment market is projected to cross the value of US$ 7.09 Bn by 2031. Acute agitation is a frequent occurrence in both inpatient and outpatient psychiatric settings. This is acting as a key driver for market growth. Manufacturers in the acute agitation and aggression treatment market are increasing their production for Lorazepam, which is a type of benzodiazepine that is being extensively used for the management of acute agitation.

Lorazepam is being publicized as a clinically effective means of treating acutely agitated patients. This medication is being frequently used as the sedative and anxiolytic of choice in inpatient settings due to its rapid onset of action when administered intravenously.

acute agitation and aggression treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Several brick and mortar pharmacies have started offering telemedicine services to help patients stock their medications during the ongoing COVID-19 pandemic. Apart from medications, healthcare providers in the acute agitation and aggression treatment market are providing non-pharmacologic de-escalation techniques including verbal de-escalation, combined with re-orientation and successive attempts at a therapeutic alliance. Sedation related adverse events, owing to medications should be overcome with increased research in well-tolerated therapeutic formulations. Manufacturers are producing Olanzapine for the treatment of agitation meant for intravenous administration. Midazolam, on the other hand, is being made available for intranasal and oral route of administration in acutely agitated patients, especially in EDs.

Acute Agitation and Aggression Treatment Market: Overview

  • This report analyzes the current scenario and future prospects of the global acute agitation and aggression treatment market. Rise in burden of mental illnesses and increase in agitation in patients are projected to boost the growth of the global acute agitation and aggression treatment market.
  • The report includes an elaborate executive summary, which provides a snapshot of various segments of the global acute agitation and aggression treatment market. It also provides information and data analysis of the acute agitation and aggression treatment market about segments based on treatment approach, route of administration, indication, end-user, and region.
  • The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that affect the global acute agitation and aggression treatment market
  • The report includes company profiles, which provide information about their business, product portfolios, and competitive landscape in the global acute agitation and aggression treatment market
  • The report on the acute agitation and aggression treatment market offers market attractiveness analysis of regions and segments
  • The last section of the report comprises quantitative and qualitative analyses on market share/position of key players operating in the global acute agitation and aggression treatment market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global acute agitation and aggression treatment market.

Acute Agitation and Aggression Treatment Market: Key Segments

  • In terms of treatment approach, the global acute agitation and aggression treatment market has been classified into behavioral approaches, environmental interventions, and pharmacologic approaches (drugs). The pharmacologic approaches (drugs) segment has been split into lorazepam, chlorpromazine, quetiapine, droperidol, olanzapine, ziprasidone, and others. The pharmacologic approaches (drugs) segment accounted for major share of the market in 2020 and the trend is anticipated to continue during the forecast period. Benefits of drugs such as ease of administration, rapid onset of action, and sufficient duration of effect are expected to boost the demand for pharmacologic approach for agitation and aggression treatment, which in turn is likely to augment the segment.
  • Based on route of administration, the global acute agitation and aggression treatment market has been categorized into oral, intramuscular, and others. The oral segment dominated the market in 2020. Growth of the segment can be attributed to the recommended usage of agitation treatment drugs in oral form.
  • In terms of indication, the global acute agitation and aggression treatment market has been segregated into schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation & aggression, alcohol withdrawal, and others. Rise in prevalence of schizophrenia is projected to drive the schizophrenia segment.
  • Based on end-user, the global acute agitation and aggression treatment market has been divided into hospitals & ambulatory surgical centers, psychiatric care facilities, and others. The hospitals & ambulatory surgical centers segment accounted for major share of the market. Rise in occurrence of agitation in hospitalized patients is anticipated to propel the segment.
  • Market size and forecast for each of these segments have been provided from 2017 to 2031. The CAGR of respective segments has also been provided from 2021 to 2031, considering 2020 as the base year.

Acute Agitation and Aggression Treatment Market: Regional Outlook

  • In terms of region, the global acute agitation and aggression treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). Each region considered in the market has been divided into countries/sub-regions.
  • The acute agitation and aggression treatment market report provides size and forecast for each region and country/sub-region from 2017 to 2031. The CAGR for each of these regions and countries has also been provided for the forecast period from 2021 to 2031. The acute agitation and aggression treatment market study also covers the competitive scenario in these regions.

Companies Covered in Acute Agitation and Aggression Treatment Market Report

  • Key players in the global acute agitation and aggression treatment market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the acute agitation and aggression treatment market report are
    • Eli Lilly and Company
    • Pfizer, Inc.
    • GlaxoSmithKline
    • Otsuka Holdings Co., Ltd.
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd
    • Amneal Pharmaceuticals LLC
    • H. Lundbeck A/S., among others.

Acute Agitation and Aggression Treatment Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 4.10 Bn

Market Forecast Value in 2031

US$ 7.09 Bn

Growth Rate (CAGR)

5.1%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

The report scope includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key industry events, product analysis, technological advancement, etc.

Competition Landscape

Company Profiles section includes overview, business overview, strategy & recent developments, key financials, etc.

Format

Electronic (PDF) + Excel

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • Argentina
  • GCC Countries
  • South Africa

Market Segmentation

  • Treatment Approach
    • Behavioral Approaches
    • Environmental Interventions
    • Pharmacologic Approaches (Drugs)
      • Lorazepam
      • Chlorpromazine
      • Quetiapine
      • Droperidol
      • Olanzapine
      • Ziprasidone
      • Others
  • Indication
    • Schizophrenia
    • Dementia
    • Bipolar Disorder
    • Depression
    • Drug-induced Agitation and Aggression
    • Alcohol Withdrawal
    • Others
  • Route of Administration
    • Oral
    • Intramuscular
    • Others
  • End User
    • Hospitals & Ambulatory Surgical Centers
    • Psychiatric Care Facilities
    • Others

Companies Profiled

  • Eli Lilly and Company
  • Pfizer, Inc.
  • Otsuka Holdings
  • GlaxoSmithKline
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Apotex, Inc.
  • Aurobindo Pharma

Customization Scope

Available upon request

Pricing

Available upon request

Acute Agitation and Aggression Treatment Market – Segmentation

Treatment Approach
  • Behavioral Approaches
  • Environmental Interventions
  • Pharmacologic Approaches (Drugs)
    • Lorazepam
    • Chlorpromazine
    • Quetiapine
    • Droperidol
    • Olanzapine
    • Ziprasidone
    • Others
Indication
  • Schizophrenia
  • Dementia
  • Bipolar Disorder
  • Depression
  • Drug-induced Agitation & Aggression
  • Alcohol Withdrawal
  • Others
Route of Administration
  • Oral
  • Intramuscular
  • Others
End-user
  • Health Care Providers
  • Psychiatric Care Facilities
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of acute agitation and aggression treatment market?

Acute agitation and aggression treatment market is projected to cross the value of US$ 7.09 Bn by 2031

What is the anticipated CAGR of the acute agitation and aggression treatment market in the forecast period?

Acute agitation and aggression treatment market is predicted to expand at a modest CAGR of 5.1% from 2021 to 2031

What are the key driving factors for the growth of the acute agitation and aggression treatment market?

Acute agitation and aggression treatment market is driven by increase in incidence of dementia in geriatric population

Which region is expected to project the highest market share in the global acute agitation and aggression treatment market?

North America is projected to account for a prominent share of the global acute agitation and aggression treatment market during the forecast period

Who are the key players in the acute agitation and aggression treatment market?

Key players in the global acute agitation and aggression treatment market include Eli Lilly and Company, Pfizer, Inc., GlaxoSmithKline, Otsuka Holdings Co., Ltd., Johnson & Johnson

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Acute Agitation and Aggression Treatment Market

    4. Market Overview

        4.1. Introduction

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Patient journey Analysis

        5.3. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)

        5.4. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

        5.5. Pros and Cons of current Treatment for Acute Agitation and Aggression

        5.6. Technological Advancements

    6. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Treatment Approach

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Treatment Approach, 2017–2031

            6.3.1. Behavioral Approaches

            6.3.2. Environmental Interventions

            6.3.3. Pharmacologic Approaches (Drugs)

                6.3.3.1. Lorazepam

                6.3.3.2. Chlorpromazine

                6.3.3.3. Quetiapine

                6.3.3.4. Droperidol

                6.3.3.5. Olanzapine

                6.3.3.6. Ziprasidone

                6.3.3.7. Others

        6.4. Market Attractiveness Analysis, by Treatment Approach

    7. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Indication

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Indication, 2017–2031

            7.3.1. Schizophrenia

            7.3.2. Dementia

            7.3.3. Bipolar Disorder

            7.3.4. Depression

            7.3.5. Drug-induced Agitation and Aggression

            7.3.6. Alcohol Withdrawal

            7.3.7. Others

        7.4. Market Attractiveness Analysis, by Indication

    8. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Route of Administration

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Route of Administration, 2017–2031

            8.3.1. Oral

            8.3.2. Intramuscular

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by Route of Administration

    9. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by End-user

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by End-user, 2017–2031

            9.3.1. Hospitals & Ambulatory Surgical Centers

            9.3.2. Psychiatric Care Facilities

            9.3.3. Others

        9.4. Market Attractiveness Analysis, by End-user

    10. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness Analysis, by Country/Region

    11. North America Acute Agitation and Aggression Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Treatment Approach, 2017–2031

            11.2.1. Behavioral Approaches

            11.2.2. Environmental Interventions

            11.2.3. Pharmacologic Approaches (Drugs)

                11.2.3.1. Lorazepam

                11.2.3.2. Chlorpromazine

                11.2.3.3. Quetiapine

                11.2.3.4. Droperidol

                11.2.3.5. Olanzapine

            11.2.4. Ziprasidone

                11.2.4.1. Others

        11.3. Market Value Forecast, by Indication, 2017–2031

            11.3.1. Schizophrenia

            11.3.2. Dementia

            11.3.3. Bipolar Disorder

            11.3.4. Depression

            11.3.5. Drug-induced Agitation and Aggression

            11.3.6. Alcohol Withdrawal

            11.3.7. Others

        11.4. Market Value Forecast, by Route of Administration, 2017–2031

            11.4.1. Oral

            11.4.2. Intramuscular

            11.4.3. Others

        11.5. Market Value Forecast, by End-user, 2017–2031

            11.5.1. Hospitals & Ambulatory Surgical Centers

            11.5.2. Psychiatric Care Facilities

            11.5.3. Others

        11.6. Market Value Forecast, by Country, 2017–2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Treatment Approach

            11.7.2. By Indication

            11.7.3. By Route of Administration

            11.7.4. By End-user

            11.7.5. By Country

    12. Europe Acute Agitation and Aggression Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Treatment Approach, 2017–2031

            12.2.1. Behavioral Approaches

            12.2.2. Environmental Interventions

            12.2.3. Pharmacologic Approaches (Drugs)

                12.2.3.1. Lorazepam

                12.2.3.2. Chlorpromazine

                12.2.3.3. Quetiapine

                12.2.3.4. Droperidol

                12.2.3.5. Olanzapine

                12.2.3.6. Ziprasidone

                12.2.3.7. Others

        12.3. Market Value Forecast, by Indication , 2017–2031

            12.3.1. Schizophrenia

            12.3.2. Dementia

            12.3.3. Bipolar Disorder

            12.3.4. Depression

            12.3.5. Drug-induced Agitation and Aggression

            12.3.6. Alcohol Withdrawal

            12.3.7. Others

        12.4. Market Value Forecast, by Route of Administration, 2017–2031

            12.4.1. Oral

            12.4.2. Intramuscular

            12.4.3. Others

        12.5. Market Value Forecast, by End-user, 2017–2031

            12.5.1. Hospitals & Ambulatory Surgical Centers

            12.5.2. Psychiatric Care Facilities

            12.5.3. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Treatment Approach

            12.7.2. By Indication

            12.7.3. By Route of Administration

            12.7.4. By End-user

            12.7.5. By Country/Sub-region

    13. Asia Pacific Acute Agitation and Aggression Treatment Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Treatment Approach, 2017–2031

            13.2.1. Behavioral Approaches

            13.2.2. Environmental Interventions

            13.2.3. Pharmacologic Approaches (Drugs)

                13.2.3.1. Lorazepam

                13.2.3.2. Chlorpromazine

                13.2.3.3. Quetiapine

                13.2.3.4. Droperidol

                13.2.3.5. Olanzapine

                13.2.3.6. Ziprasidone

                13.2.3.7. Others

        13.3. Market Value Forecast, by Indication, 2017–2031

            13.3.1. Schizophrenia

            13.3.2. Dementia

            13.3.3. Bipolar Disorder

            13.3.4. Depression

            13.3.5. Drug-induced Agitation and Aggression

            13.3.6. Alcohol Withdrawal

            13.3.7. Others

        13.4. Market Value Forecast, by Route of Administration , 2017–2031

            13.4.1. Oral

            13.4.2. Intramuscular

            13.4.3. Others

        13.5. Market Value Forecast, by End-user, 2017–2031

            13.5.1. Hospitals & Ambulatory Surgical Centers

            13.5.2. Psychiatric Care Facilities

            13.5.3. Others

        13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Treatment Approach

            13.7.2. By Indication

            13.7.3. By Route of Administration

            13.7.4. By End-user

            13.7.5. By Country/Sub-region

    14. Latin America Acute Agitation and Aggression Treatment Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Treatment Approach, 2017–2031

            14.2.1. Behavioral Approaches

            14.2.2. Environmental Interventions

            14.2.3. Pharmacologic Approaches (Drugs)

                14.2.3.1. Lorazepam

                14.2.3.2. Chlorpromazine

                14.2.3.3. Quetiapine

                14.2.3.4. Droperidol

                14.2.3.5. Olanzapine

            14.2.4. Ziprasidone

                14.2.4.1. Others

        14.3. Market Value Forecast, by Indication , 2017–2031

            14.3.1. Schizophrenia

            14.3.2. Dementia

            14.3.3. Bipolar Disorder

            14.3.4. Depression

            14.3.5. Drug-induced Agitation and Aggression

            14.3.6. Alcohol Withdrawal

            14.3.7. Others

        14.4. Market Value Forecast, by Route of Administration , 2017–2031

            14.4.1. Oral

            14.4.2. Intramuscular

            14.4.3. Others

        14.5. Market Value Forecast, by End-user, 2017–2031

            14.5.1. Hospitals & Ambulatory Surgical Centers

            14.5.2. Psychiatric Care Facilities

            14.5.3. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Treatment Approach

            14.7.2. By Indication

            14.7.3. By Route of Administration

            14.7.4. By End-user

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Acute Agitation and Aggression Treatment Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Treatment Approach, 2017–2031

            15.2.1. Behavioral Approaches

            15.2.2. Environmental Interventions

            15.2.3. Pharmacologic Approaches (Drugs)

                15.2.3.1. Lorazepam

                15.2.3.2. Chlorpromazine

                15.2.3.3. Quetiapine

                15.2.3.4. Droperidol

                15.2.3.5. Olanzapine

            15.2.4. Ziprasidone

                15.2.4.1. Others

        15.3. Market Value Forecast, by Indication, 2017–2031

            15.3.1. Schizophrenia

            15.3.2. Dementia

            15.3.3. Bipolar Disorder

            15.3.4. Depression

            15.3.5. Drug-induced Agitation and Aggression

            15.3.6. Alcohol Withdrawal

            15.3.7. Others

        15.4. Market Value Forecast, by Route of Administration, 2017–2031

            15.4.1. Oral

            15.4.2. Intramuscular

            15.4.3. Others

        15.5. Market Value Forecast, by End-user, 2017–2031

            15.5.1. Hospitals and Ambulatory Surgical Centers

            15.5.2. Psychiatric Care Facilities

            15.5.3. Others

        15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Treatment Approach

            15.7.2. By Indication

            15.7.3. By Route of Administration

            15.7.4. By End-user

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player - Competition Matrix (by tier and size of companies)

        16.2. Company Profiles

            16.2.1. Eli Lilly and Company

                16.2.1.1. Company Overview

                16.2.1.2. Company Financials

                16.2.1.3. Growth Strategies

                16.2.1.4. SWOT Analysis

            16.2.2. Pfizer, Inc.

                16.2.2.1. Company Overview

                16.2.2.2. Company Financials

                16.2.2.3. Growth Strategies

                16.2.2.4. SWOT Analysis

            16.2.3. Otsuka Holdings

                16.2.3.1. Company Overview

                16.2.3.2. Company Financials

                16.2.3.3. Growth Strategies

                16.2.3.4. SWOT Analysis

            16.2.4. GlaxoSmithKline

                16.2.4.1. Company Overview

                16.2.4.2. Company Financials

                16.2.4.3. Growth Strategies

                16.2.4.4. SWOT Analysis

            16.2.5. H. Lundbeck A/S

                16.2.5.1. Company Overview

                16.2.5.2. Company Financials

                16.2.5.3. Growth Strategies

                16.2.5.4. SWOT Analysis

            16.2.6. Johnson & Johnson

                16.2.6.1. Company Overview

                16.2.6.2. Company Financials

                16.2.6.3. Growth Strategies

                16.2.6.4. SWOT Analysis

            16.2.7. Teva Pharmaceutical Industries Ltd.

                16.2.7.1. Company Overview

                16.2.7.2. Company Financials

                16.2.7.3. Growth Strategies

                16.2.7.4. SWOT Analysis

            16.2.8. Amneal Pharmaceuticals LLC

                16.2.8.1. Company Overview

                16.2.8.2. Company Financials

                16.2.8.3. Growth Strategies

                16.2.8.4. SWOT Analysis

            16.2.9. Sun Pharmaceutical Industries Ltd.

                16.2.9.1. Company Overview

                16.2.9.2. Company Financials

                16.2.9.3. Growth Strategies

                16.2.9.4. SWOT Analysis

            16.2.10. F. Hoffmann-La Roche Ltd.

                16.2.10.1. Company Overview

                16.2.10.2. Company Financials

                16.2.10.3. Growth Strategies

                16.2.10.4. SWOT Analysis

            16.2.11. Bausch Health Companies, Inc.

                16.2.11.1. Company Overview

                16.2.11.2. Company Financials

                16.2.11.3. Growth Strategies

                16.2.11.4. SWOT Analysis

            16.2.12. Apotex, Inc.

                16.2.12.1. Company Overview

                16.2.12.2. Company Financials

                16.2.12.3. Growth Strategies

                16.2.12.4. SWOT Analysis

            16.2.13. Aurobindo Pharma

                16.2.13.1. Company Overview

                16.2.13.2. Company Financials

                16.2.13.3. Growth Strategies

                16.2.13.4. SWOT Analysis

    List of Tables

    Table 01: Pipeline Analysis - Acute Agitation and Aggression Treatment

    Table 02: Oral Medications For Clinically Significant Acute Agitation

    Table 03: Parenteral Medications For Clinically Significant Acute Agitation

    Table 04: Pros and Cons of Non-pharmacologic Interventions for Acute Agitation

    Table 05: Pros and Cons of Pharmacologic Interventions (Different routes of administration) For Acute Agitation

    Table 06: Pros and Cons of Pharmacologic Interventions (Oral) For Acute Agitation

    Table 07: Pros and Cons of Pharmacologic Interventions For Acute Agitation

    Table 08: Pharmacology of drugs commonly used for Acute Agitation and Aggression

    Table 09: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031

    Table 10: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031

    Table 11: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 12: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 13: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 14: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 15: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031

    Table 16: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031

    Table 17: North America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 18: North America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

    Table 19: North America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    Table 20: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 21: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031

    Table 22: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031

    Table 23: Europe Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 24: Europe Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

    Table 25: Europe Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    Table 26: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 27: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031

    Table 28: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031

    Table 29: Asia Pacific Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 30: Asia Pacific Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

    Table 31: Asia Pacific Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    Table 32: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 33: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031

    Table 34: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031

    Table 35: Latin America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 36: Latin America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

    Table 37: Latin America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    Table 38: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 39: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031

    Table 40: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031

    Table 41: Middle East & Africa Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 42: Middle East & Africa Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

    Table 43: Middle East & Africa Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Acute Agitation and Aggression Treatment Market Value Share, by Treatment Approach, 2020

    Figure 03: Global Acute Agitation and Aggression Treatment Market Value Share, by Route of Administration, 2020

    Figure 04: Global Acute Agitation and Aggression Treatment Market Value Share, by End-user, 2020

    Figure 05: Global Acute Agitation and Aggression Treatment Market Value Share, by Indication , 2020

    Figure 06: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031

    Figure 07: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031

    Figure 08: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Behavioral Approaches, 2017–2031

    Figure 09: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Environmental Interventions, 2017–2031

    Figure 10: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Pharmacologic Approaches (Drugs), 2017–2031

    Figure 11: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Lorazepam, 2017–2031

    Figure 12: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Chlorpromazine, 2017–2031

    Figure 13: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Quetiapine, 2017–2031

    Figure 14: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Droperidol, 2017–2031

    Figure 15: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Olanzapine, 2017–2031

    Figure 16: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Ziprasidone, 2017–2031

    Figure 17: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Others, 2017–2031

    Figure 18: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 19: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 20: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Oral, 2017–2031

    Figure 21: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Intramuscular, 2017–2031

    Figure 22: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Others, 2017–2031

    Figure 23: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 24: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 25: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Schizophrenia, 2017–2031

    Figure 26: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Dementia, 2017–2031

    Figure 27: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Bipolar Disorder, 2017–2031

    Figure 28: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Depression , 2017–2031

    Figure 29: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Drug-induced agitation and aggression, 2017–2031

    Figure 30: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Alcohol withdrawal, 2017–2031

    Figure 31: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Others, 2017–2031

    Figure 32: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 33: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 34: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Hospitals & Ambulatory Surgical Centers, 2017–2031

    Figure 35: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Psychiatric Care Facilities, 2017–2031

    Figure 36: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 37: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Others, 2017–2031

    Figure 38: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country, 2020 and 2031

    Figure 39: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country, 2021–2031

    Figure 40: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031

    Figure 41: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031

    Figure 42: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 43: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 44: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 45: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 46: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 47: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 48: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 49: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

    Figure 50: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 51: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031

    Figure 52: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031

    Figure 53: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 54: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 55: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 56: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 57: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 58: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 59: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 60: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

    Figure 61: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 62: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031

    Figure 63: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031

    Figure 64: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 65: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 66: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 67: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 68: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 69: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 70: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 71: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

    Figure 72: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 73: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031

    Figure 74: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031

    Figure 75: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 76: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 77: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 78: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 79: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 80: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 81: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 82: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

    Figure 83: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 84: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031

    Figure 85: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031

    Figure 86: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031

    Figure 87: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031

    Figure 88: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 89: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 90: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 91: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031

Copyright © Transparency Market Research, Inc. All Rights reserved